Skip to main content
Erschienen in: Journal of General Internal Medicine 12/2016

27.06.2016 | Clinical Practice: Clinical Vignettes

Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin

verfasst von: Lori W. Lee, PhD, Neera S. Narang, MD, Anna Postolova, MD, Nicole Seminara, MD, Molly A. Kantor, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

ABSTRACT

Dermatomyositis is a chronic systemic autoimmune disease characterized by inflammatory infiltrates in the skin and muscle. The wide variability in clinical and serologic presentation poses a diagnostic challenge for the internist. Appreciation of the clinical variants of dermatomyositis allows for expedient diagnosis and avoidance of diagnostic error. We illustrate these challenges with the case of a 51-year-old Vietnamese-American man who initially presented with fever of unknown origin in the absence of overt skin and muscle manifestations. The diagnosis of dermatomyositis was not evident on several clinical encounters due to the absence of these hallmark symptoms. We review the variable clinical manifestations of a subtype of dermatomyositis associated with an autoantibody against melanoma differentiation-associated protein 5 (anti-MDA5) and suggest consideration of dermatomyositis as a diagnosis in patients presenting with systemic illness and markedly elevated ferritin, even in the absence of elevated muscle enzymes and classic autoantibodies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jordan MB, Allen CE, Weitzman S, Filipovich AH, Mcclain KL. How I treat How I treat hemophagocytic lymphohistiocytosis. 2011;118:4041–4052. Jordan MB, Allen CE, Weitzman S, Filipovich AH, Mcclain KL. How I treat How I treat hemophagocytic lymphohistiocytosis. 2011;118:4041–4052.
2.
Zurück zum Zitat Henter J-I, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131.CrossRefPubMed Henter J-I, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131.CrossRefPubMed
3.
Zurück zum Zitat Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48:607–612.CrossRefPubMed Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48:607–612.CrossRefPubMed
4.
Zurück zum Zitat Fujikawa K, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009;38:263–267.CrossRefPubMed Fujikawa K, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009;38:263–267.CrossRefPubMed
5.
Zurück zum Zitat Targoff IN. Idiopathic inflammatory myopathy: autoantibody update. Curr Rheumatol Rep. 2002;4:434–441.CrossRefPubMed Targoff IN. Idiopathic inflammatory myopathy: autoantibody update. Curr Rheumatol Rep. 2002;4:434–441.CrossRefPubMed
6.
Zurück zum Zitat Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25–34.CrossRefPubMedPubMedCentral Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25–34.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Chen Z, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65:1316–1324.CrossRef Chen Z, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65:1316–1324.CrossRef
8.
Zurück zum Zitat Gono T, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol. (United Kingdom). 2012;51:1563–1570. Gono T, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol. (United Kingdom). 2012;51:1563–1570.
9.
Zurück zum Zitat Sato S, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–1576.CrossRefPubMed Sato S, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–1576.CrossRefPubMed
10.
Zurück zum Zitat Sato S, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193–2200.CrossRefPubMed Sato S, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193–2200.CrossRefPubMed
11.
Zurück zum Zitat Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol. 2010;22:639–643.CrossRefPubMed Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol. 2010;22:639–643.CrossRefPubMed
12.
Zurück zum Zitat Cao H, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res. 2012;64:1602–1610.CrossRef Cao H, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res. 2012;64:1602–1610.CrossRef
13.
Zurück zum Zitat Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 2015; 67:667-672. Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 2015; 67:667-672.
14.
Zurück zum Zitat Koga T, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatol. (United Kingdom). 2012;51:1278–1284. Koga T, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatol. (United Kingdom). 2012;51:1278–1284.
15.
Zurück zum Zitat Hamaguchi Y, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–398.CrossRefPubMed Hamaguchi Y, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–398.CrossRefPubMed
16.
Zurück zum Zitat Gono T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49:1713–1719.CrossRefPubMed Gono T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49:1713–1719.CrossRefPubMed
17.
Zurück zum Zitat Hall JC, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65:1307–1315.CrossRef Hall JC, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65:1307–1315.CrossRef
18.
Zurück zum Zitat Nakashima R, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2009;49:433–440.CrossRefPubMed Nakashima R, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2009;49:433–440.CrossRefPubMed
19.
Zurück zum Zitat Tanizawa K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105:1380–1387.CrossRefPubMed Tanizawa K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105:1380–1387.CrossRefPubMed
20.
Zurück zum Zitat Ikeda N, et al. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 2011;38:973–979.CrossRefPubMed Ikeda N, et al. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 2011;38:973–979.CrossRefPubMed
21.
Zurück zum Zitat Ponyi A, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci. 2005;1051:64–71.CrossRefPubMed Ponyi A, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci. 2005;1051:64–71.CrossRefPubMed
22.
Zurück zum Zitat Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7:343–354.CrossRefPubMed Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7:343–354.CrossRefPubMed
23.
Zurück zum Zitat Hu WJ, Chen DL, Min HQ. Study of 45 cases of nasopharyngeal carcinoma with dermatomyositis. Am J Clin Oncol. 1996;19:35–38.CrossRefPubMed Hu WJ, Chen DL, Min HQ. Study of 45 cases of nasopharyngeal carcinoma with dermatomyositis. Am J Clin Oncol. 1996;19:35–38.CrossRefPubMed
24.
Zurück zum Zitat Huang YL, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol. 2009;161:854–860.CrossRefPubMed Huang YL, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol. 2009;161:854–860.CrossRefPubMed
25.
Zurück zum Zitat Redelmeier DA. Improving patient care. The cognitive psychology of missed diagnoses. Ann Intern Med. 2005;142:115–120.CrossRefPubMed Redelmeier DA. Improving patient care. The cognitive psychology of missed diagnoses. Ann Intern Med. 2005;142:115–120.CrossRefPubMed
26.
Zurück zum Zitat Endsley MR. Toward a theory of situation awareness in dynamic systems. Hum Factors J Hum Factors Ergon Soc. 1995;37:32–64.CrossRef Endsley MR. Toward a theory of situation awareness in dynamic systems. Hum Factors J Hum Factors Ergon Soc. 1995;37:32–64.CrossRef
27.
Zurück zum Zitat Smith K, Hancock PA. Situation awareness is adaptive, externally directed consciousness. Hum Factors J Hum Factors Ergon Soc. 1995;37:137–148.CrossRef Smith K, Hancock PA. Situation awareness is adaptive, externally directed consciousness. Hum Factors J Hum Factors Ergon Soc. 1995;37:137–148.CrossRef
28.
Zurück zum Zitat Hazlehurst B, McMullen CK, Gorman PN. Distributed cognition in the heart room: how situation awareness arises from coordinated communications during cardiac surgery. J Biomed Inform. 2007;40:539–551.CrossRefPubMed Hazlehurst B, McMullen CK, Gorman PN. Distributed cognition in the heart room: how situation awareness arises from coordinated communications during cardiac surgery. J Biomed Inform. 2007;40:539–551.CrossRefPubMed
29.
Zurück zum Zitat Stanton NA, Chambers PRG, Piggott J. Situational awareness and safety. Saf Sci. 2001;39:189–204.CrossRef Stanton NA, Chambers PRG, Piggott J. Situational awareness and safety. Saf Sci. 2001;39:189–204.CrossRef
30.
Zurück zum Zitat Stanton NA, et al. Distributed situation awareness in dynamic systems: theoretical development and application of an ergonomics methodology. Ergonomics. 2007;49:1288–1311.CrossRef Stanton NA, et al. Distributed situation awareness in dynamic systems: theoretical development and application of an ergonomics methodology. Ergonomics. 2007;49:1288–1311.CrossRef
31.
Zurück zum Zitat Hancock PA, Szalma JL. Operator stress and display design. Ergon Des. 2003;11:13–18. Hancock PA, Szalma JL. Operator stress and display design. Ergon Des. 2003;11:13–18.
33.
Zurück zum Zitat Fukukura J, Ferguson MJ, Fujita K. Psychological distance can improve decision making under information overload via gist memory. J Exp Psychol Gen. 2012;142:658–665.CrossRefPubMed Fukukura J, Ferguson MJ, Fujita K. Psychological distance can improve decision making under information overload via gist memory. J Exp Psychol Gen. 2012;142:658–665.CrossRefPubMed
34.
Zurück zum Zitat Bawden D, Robinson L. The dark side of information: overload, anxiety and other paradoxes and pathologies. J Inf Sci. 2008;35:180–191.CrossRef Bawden D, Robinson L. The dark side of information: overload, anxiety and other paradoxes and pathologies. J Inf Sci. 2008;35:180–191.CrossRef
35.
Zurück zum Zitat Case DO, Andrews JE, Johnson JD, Allard SL. Avoiding versus seeking: the relationship of information seeking to avoidance, blunting, coping, dissonance, and related concepts. J Med Libr Assoc. 2005;93:353–62.PubMedPubMedCentral Case DO, Andrews JE, Johnson JD, Allard SL. Avoiding versus seeking: the relationship of information seeking to avoidance, blunting, coping, dissonance, and related concepts. J Med Libr Assoc. 2005;93:353–62.PubMedPubMedCentral
36.
Zurück zum Zitat Singh H, Naik AD, Rao R, Petersen LA. Reducing diagnostic errors through effective communication: harnessing the power of information technology. J Gen Intern Med. 2008;23:489–494.CrossRefPubMedPubMedCentral Singh H, Naik AD, Rao R, Petersen LA. Reducing diagnostic errors through effective communication: harnessing the power of information technology. J Gen Intern Med. 2008;23:489–494.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Jain A, et al. Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol Scand. 2011;123:122–129.CrossRefPubMed Jain A, et al. Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol Scand. 2011;123:122–129.CrossRefPubMed
38.
Zurück zum Zitat Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies characterization of the Jo- 1 antibody system. Arthritis Rheum. 1980;23:881–888.CrossRefPubMed Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies characterization of the Jo- 1 antibody system. Arthritis Rheum. 1980;23:881–888.CrossRefPubMed
39.
Zurück zum Zitat Yoshida S, et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26:604–611.CrossRefPubMed Yoshida S, et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26:604–611.CrossRefPubMed
40.
Zurück zum Zitat Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000;12:475–481.CrossRefPubMed Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000;12:475–481.CrossRefPubMed
42.
Zurück zum Zitat Nakashima R, Mimori T. Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. Int J Clin Rheumatol. 2010;5:523–536.CrossRef Nakashima R, Mimori T. Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. Int J Clin Rheumatol. 2010;5:523–536.CrossRef
43.
Zurück zum Zitat Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985;28:796–803.CrossRefPubMed Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985;28:796–803.CrossRefPubMed
44.
Zurück zum Zitat Iaccarino L, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. 2014;48–49:122–127.CrossRefPubMed Iaccarino L, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. 2014;48–49:122–127.CrossRefPubMed
45.
Zurück zum Zitat Love LA, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360–374.CrossRef Love LA, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360–374.CrossRef
46.
Zurück zum Zitat Betteridge ZE, et al. Autoantibodies to the p140 autoantigen NXP-2 in adult dermatomyositis. Arthritis Rheum. 2009;60:815. Betteridge ZE, et al. Autoantibodies to the p140 autoantigen NXP-2 in adult dermatomyositis. Arthritis Rheum. 2009;60:815.
47.
Zurück zum Zitat Fiorentino DF, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65:2954–62.CrossRefPubMedPubMedCentral Fiorentino DF, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65:2954–62.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Ichimura Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710–713.CrossRefPubMed Ichimura Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710–713.CrossRefPubMed
49.
Zurück zum Zitat Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56:3132–7.CrossRefPubMed Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56:3132–7.CrossRefPubMed
50.
Zurück zum Zitat Tarricone E, et al. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods. 2012;384:128–134.CrossRefPubMed Tarricone E, et al. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods. 2012;384:128–134.CrossRefPubMed
51.
Zurück zum Zitat Ghirardello A, et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlight. 2014;5:69–75.CrossRef Ghirardello A, et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlight. 2014;5:69–75.CrossRef
52.
Zurück zum Zitat Betteridge ZE, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68:1621–5.CrossRefPubMed Betteridge ZE, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68:1621–5.CrossRefPubMed
53.
Zurück zum Zitat Fujimoto M, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis. Arthritis Rheum. 2012;64:S97. Fujimoto M, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis. Arthritis Rheum. 2012;64:S97.
54.
Zurück zum Zitat Targoff IN, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–3689.CrossRefPubMed Targoff IN, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–3689.CrossRefPubMed
55.
Zurück zum Zitat Fujimoto M, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64:513–22.CrossRefPubMed Fujimoto M, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64:513–22.CrossRefPubMed
56.
Zurück zum Zitat Trallero-Araguás E, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64:523–532.CrossRefPubMed Trallero-Araguás E, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64:523–532.CrossRefPubMed
57.
Zurück zum Zitat Trallero-Araguás E, et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore). 2010;89:47–52.CrossRef Trallero-Araguás E, et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore). 2010;89:47–52.CrossRef
58.
Zurück zum Zitat Gunawardena H, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008;47:324–8.CrossRef Gunawardena H, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008;47:324–8.CrossRef
59.
Zurück zum Zitat Mack A, Rock I. Inattentional Blindness. In: Malik J, Perona P, eds. Cambridge MA, MIT Press; 1998:7, 287 Mack A, Rock I. Inattentional Blindness. In: Malik J, Perona P, eds. Cambridge MA, MIT Press; 1998:7, 287
Metadaten
Titel
Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin
verfasst von
Lori W. Lee, PhD
Neera S. Narang, MD
Anna Postolova, MD
Nicole Seminara, MD
Molly A. Kantor, MD
Publikationsdatum
27.06.2016
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 12/2016
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-016-3769-0

Weitere Artikel der Ausgabe 12/2016

Journal of General Internal Medicine 12/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.